JLLC «TRIPLEPHARM» - HEALTH FIRST!

Reliable choice in treatment of acquired microbial resistance. Especially active against gram-negative (-) bacteria. Most active against Pseudomonas aeruginosa, Acinetobacter baumannii, Citrobacter spp. Used parenterally in treatment of serious infections of lower respiratory tract and urinary system when widely used systemic antibiotics are ineffective because of development of bacterial resistance. Inhalational administration is recommended for patients with mucoviscidosis.

Reliable choice in treatment of acquired microbial resistance. Especially active against gram-negative (-) bacteria. Most active against Pseudomonas aeruginosa, Acinetobacter baumannii, Citrobacter spp. Used parenterally in treatment of serious infections of lower respiratory tract and urinary system when widely used systemic antibiotics are ineffective because of development of bacterial resistance. Inhalational administration is recommended for patients with mucoviscidosis.

A highly potent carbapenem antibiotic drug. Active against gram-positive (+) and gram-negative (-) aerobic and anaerobic bacteria. Several times more active against Pseudomonas aeruginosa compared to meropenem and imipenem/cilastatin. Used in treatment of hospital-acquired (nosocomial) pneumonia, including ventilator-associated pneumonia; complicated intraabdominal infections; complicated infections of urinary system, including complicated and uncomplicated pyelonephritis, particularly pyelonephritis with accompanying bacteremia.

An ultra-wide range of antibacterial activity includes practically all significant gram-positive (+) and gram-negative (-) aerobic and anaerobic microorganisms. Non-neurotoxic. Used for de-escalation therapy of serious infections of lower respiratory tract, intraabdominal infections, gynecological infections, skin and soft tissue infections, meningitis, septicemia, empiric treatment in patients with neutropenia, as monotherapy or in combination with antiviral or antifungal pharmaceutical products.